

March 2022 PDL/DUR Board Meeting Minutes

Date: March 23, 2022

Members Present: King, Brown, Blank, Jost, Caldwell, McGrane, Nauts, Stone, Putsch

Members Absent: Blake, Maxwell, Anglim

Others Present: Shannon Sexauer, Dani Feist, Katie Hawkins (DPHHS); Kathy Novak (Magellan); Artis, Bahny, Barnhill, Doppler, Dotseth, Miranda, Woodmansey (MPQHF); and representatives from the pharmaceutical industry.

Introductions: Tony King opened the meeting.

Meeting Minute Review: The meeting minutes from the February 23, 2022 DUR Board meeting were approved as written.

Public Comment: Speaker information is as follows:

- Charlie Lovan, Abbvie - Rinvoq®
- Phil Wettestad, Novartis - Leqvio®
- Dylan Bassett, Pierre Fabre Pharmaceuticals - Hemangeol®
- John Mathis, Xeris - GVoke®
- Nathan Roe, Horizon Therapeutics - Krystexxa®
- Lois Perry, US Hereditary Angioedema Association (HAEA) – HAE therapy overview
- David Armstrong, Ascendis Pharma, Inc. - Skytrofa®

Department Update: No Department update.

PREFERRED DRUG LIST MEETING

The Board reaffirmed their preference to remove the phrase “may add others” from recommendations as they felt it was unnecessary.

Results of the Board review of Group 3 (**Red category**):

CLASS	DRUGS Reviewed	2022 RECOMMENDATIONS	Grandfather
ANGIOTENSIN MODULATORS & COMBO	NI-Diovan®	<u>Angiotensin Modulator Combinations:</u> Therapeutic alternatives. <u>Angiotensin II Receptor Blockers & Combinations:</u> Therapeutic alternatives. <u>ACE Inhibitors & Combinations:</u> Class effect. Do Not Add Tekturna® or Tekturna® HCT (due to aliskiren).	NO
ANTICOAGULANTS	NI-Xarelto® NI-Pradaxa®	Must have one LMWH, warfarin, Eliquis®, and Xarelto®.	NO
BILE SALTS	ND-Bylvay®	Must have one ursodiol.	NO

	ND-Livmarli® NI-Ocaliva®		
COLONY STIMULATING FACTORS	FDA Communication	Changed to: Therapeutic alternatives. Must have one filgrastim agent and one pegfilgrastim agent. <i>Changed from Therapeutic alternatives.</i>	NO
GROWTH HORMONE	ND-Skytrofa®	Therapeutic alternatives.	NO
HYPOGLYCEMICS, INCRETIN MIMETICS/ENHANCERS	NI-Bydureon®	<u>DPP-IV Inhibitors:</u> Therapeutic alternatives. Must have one single ingredient agent. <u>GLP-1 & Combinations:</u> Therapeutic alternatives. Must have one single ingredient agent. Must have one agent with cardiovascular benefit.	NO
HYPOGLYCEMICS, INSULINS	NI-Semglee®	Class effect for each group. Must have one from each. (Human R, N, Rapid-acting, Long-Acting, Rapid/Intermediate, Reg/Intermediate Combos). Must have U-500 pen, do not add U-500 vial.	NO
HYPOGLYCEMICS, SGLT2	NI-Farxiga® NI-Jardiance®	Must have one agent with cardiovascular disease benefit. All others class effect. Continue existing Prior Authorization (PA) criteria for class.	NO
LIPOTROPICS, OTHER	ND-Leqvio® NI-Praluent® NI-Repatha®	Must have gemfibrozil and one fenofibrate.	NO
PAH AGENTS: ORAL AND INHALED	NI-Tyvaso® NI-Uptravi®	Must have one ERA and one PDE-5. Retain GF & existing PA criteria.	YES
PROTON PUMP INHIBITORS/H. PYLORI AGENTS	Safety	Class effect.	NO

The Board requested that the criteria for the Hypoglycemics,SGLT2 category class be reviewed at a future DUR meeting.

The Board reviewed the **blue category** in advance of the meeting- Kathy from Magellan reported on new doses and discontinued items in this category. This category of drugs has no new clinically significant information since last review. Board recommendations for Group 2 (Blue category) from 2021 were retained, with the exception of the lipotropics: statins and combos. Ezetimibe is housed under statins because of the combination product. The Board requested we add “must have ezetimibe” to the recommendations for this class. Blue category recommendations are as follows:

CLASS	2022 RECOMMENDATIONS	Grandfather
ANDROGENIC AGENTS, TOPICAL	Class effect.	NO
ANTIEMETICS	Must have one 5-HT3 agent and one metoclopramide product. Continue with existing PA criteria.	NO
ANTIHYPERURICEMICS	Must have allopurinol and a single ingredient colchicine product. Continue with existing PA criteria.	NO

ANTI-ANGINAL/ANTI-ISCHEMIC AGENTS	May add with PA criteria.	NO
BETA-BLOCKERS	Must have metoprolol ER and carvedilol in some form. All other single ingredient agents have a class effect. Do not add combo agents containing diuretics-not first line agents and issues of concern with thiazides.	NO
BONE RESORPTION SUPPRESSION & RELATED AGENTS	<u>Nasal Calcitonins</u> : Class effect with existing PA criteria. <u>Bisphosphonates & Bone Resorption</u> . Others: Class effect.	NO
CALCIUM CHANNEL BLOCKERS (DHP & non-DHP) and COMBOS	Must have a long-acting diltiazem and a long-acting verapamil. Must have amlodipine. All others are class effect.	NO
ERYTHROPOIESIS STIMULATING AGENTS-HEMATOPOIETIC AGENTS	Therapeutic alternatives.	NO
ESTROGEN: ORAL, TRANSDERMAL, & VAGINAL	<u>ORAL/TRANSDERMAL</u> : Class effect. Must have one topical and one oral. <u>VAGINAL</u> : Therapeutic alternatives.	NO
GI MOTILITY, CHRONIC	Therapeutic alternatives for each of the following categories: OIC: Movantik [®] , Relistor [®] , Amitiza [®] , Symproic [®] IBS-D: Alosetron [®] , Viberzi [®] IBS-C/CIC: Amitiza [®] , Linzess [®] , Trulance [®] , Motegrity [®] Continue with existing PA Criteria.	NO
GLUCAGON AGENTS	Therapeutic alternatives.	NO
HAE TREATMENT	Therapeutic alternatives. Must include one on-demand treatment and one prophylactic treatment. Continue with existing PA criteria.	NO
HYPOGLYCEMICS: ALPHA GLUCOSIDASE INHIBITORS	Class effect.	NO
HYPOGLYCEMICS: MEGLITINIDES	Class effect.	NO
HYPOGLYCEMICS: METFORMINS	Must have metformin IR. Class effect for others.	NO
HYPOGLYCEMICS: SULFONYLUREAS	Class effect.	NO
HYPOGLYCEMICS: TZDs	Class effect. Continue with existing PA criteria.	NO
LIPOTROPICS: STATINS & COMBOS	Must have 1 high potency agent, must have ezetimibe.	NO
PANCREATIC ENZYMES	Class effect with patients being grandfathered on current treatment.	YES
PHOSPHATE BINDERS	Class effect.	NO
PLATELET AGGREGATION INHIBITORS	Must have immediate release aspirin. Must have one of prasugrel, clopidogrel, ticagrelor, or vorapaxar. Class effect for other agents. Grandfathered	YES
POTASSIUM BINDERS	Therapeutic alternatives.	NO

PROGESTINS FOR CACHEXIA	Class effect.	NO
ULCERATIVE COLITIS AGENTS	Class effect. Must have more than one route.	NO

Two **green categories** were not reviewed as all chemical entities are preferred at this time. Uterine Disorder Treatments will be brought back in May for a full review.

Class
IDIOPATHIC PULMONARY FIBROSIS
UTERINE DISORDER TREATMENTS

Meeting adjourned at 2:30 p.m.

Next meeting will be April 27, 2022. It is currently set for the same format. Additional information will be posted by the Department.